NASDAQ:ARCT   Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc . $ARCT is set to be EBITDA positive in 2022 with a massive change in its revenue from 24.05M in 2021 to 326.44M in 2022. This is 12.57x increase in revenue. These numbers are estimates, but even with a large error margin we should see a drastic change in the price. Moreover, the decline from ATH was 80% and the price has been in a sideways movement after it bottomed. With today's strong breakout of the descending channel , I am expecting the price to start its rise up to the upper band of the range-bound around $63. The long-term targets should be a lot higher.

The breakout setup entry provides us with an awesome +3 Reward/Risk. A tighter stop loss order can even make it a lot better. A late entry at current prices provides 1.8-2.0 which is still a good ratio.

BioTech stocks are risky and volatile. This is not financial advice. DYODD


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.